Who are Lenvatinib plus TACE's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenvatinib-plus-tace.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lenvatinib plus TACE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lenvatinib plus TACE (Lenvatinib plus TACE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-targeted tyrosine kinase inhibitor (in combination with transarterial chemoembolization). Area: Oncology.

phase 3 Multi-targeted tyrosine kinase inhibitor (in combination with transarterial chemoembolization) FGFR, VEGFR, RET, KIT, and other receptor tyrosine kinases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lenvatinib plus TACE (Lenvatinib plus TACE) — Second Affiliated Hospital of Guangzhou Medical University. Lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth, combined with TACE (transarterial chemoembolization) to deliver chemotherapy directly to hepatic tumors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lenvatinib plus TACE TARGET	Lenvatinib plus TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-targeted tyrosine kinase inhibitor (in combination with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT, and other receptor tyrosine kinases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-targeted tyrosine kinase inhibitor (in combination with transarterial chemoembolization) class)

Second Affiliated Hospital of Guangzhou Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenvatinib plus TACE — Competitive Intelligence Brief. https://druglandscape.com/ci/lenvatinib-plus-tace. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing